Long-Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons.
Craig M McDonald, Michela Guglieri, Dragana Vučinić...
https://pubmed.ncbi.nlm.nih.gov/40830818/Actively Recruiting
Led by Italfarmaco · Updated on 2026-01-21
206
Participants Needed
39
Research Sites
N/A
Total Duration
Researchers are evaluating the long-term safety, tolerability, and effectiveness of Givinostat in patients with Duchenne Muscular Dystrophy DMD who have already participated in previous Givinostat studies. This open-label trial focuses on patients who have been previously treated with Givinostat, aiming to monitor ongoing effects and any adverse events over an extended period. Participants will take an oral suspension of Givinostat 10 mgmL twice daily while in a fed state. The starting dose will match what each patient received at the end of their prior Givinostat study and may be adjusted based on their weight and safety monitoring, especially platelet counts. Dose reductions or treatment interruptions may occur if certain safety concerns arise, such as severe diarrhea, serious adverse events, or specific blood count thresholds. The study includes weekly platelet monitoring during the first month and biweekly during the second month, with adjustments as needed. Throughout the study, participants will be closely monitored with regular evaluations of safety and tolerability, including blood tests to check platelet counts, white blood cells, hemoglobin, and heart rhythm QTcF intervals. Researchers will track the incidence of treatment-emergent adverse events over an average of one year. The investigator will manage any safety concerns and follow participants until any issues resolve or stabilize, after which participants will complete the study with an end-of-study visit. The total participation duration may vary based on individual progress and safety outcomes.
CONDITIONS
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
R
Reference Study ID Number: DSC/14/2357/51
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Italfarmaco
Lead Sponsor
Cromsource
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Givinostat (oral, investigational) | Standard Therapy: Corticosteroids |
|---|---|---|
| What it is | An investigational oral suspension of Givinostat provided to children and adolescents with DMD who had participated in prior Givinostat trials or qualified as off-target from previous protocols. | Long-term corticosteroid medication (such as prednisone or deflazacort) is the established standard therapy for DMD, prescribed for most patients following diagnosis and typically continued long-term. |
| Role in study | Main study drug given to eligible participants to evaluate long-term safety and tolerability. | Provided as usual care in clinical practice, serving as a comparator for long-term DMD clinical outcomes in external studies. |
| Primary use | Studied for potential to improve or maintain muscle function and slow disease progression in DMD when added to background therapy. | Used to help maintain muscle strength, delay progression of weakness, and manage symptoms in DMD. |
| How it is given or performed | Oral liquid suspension given daily, with the dose adjusted based on participant's weight and lab results, per protocol safety rules. | Oral tablets or liquid, usually taken once daily as part of routine long-term DMD management. The specific drug and dose are determined according to clinical guidelines and patient factors. |
| Evidence status | Ongoing trial and publication report observational data with extension follow-up, comparing outcomes in Givinostat-treated patients to natural history groups. Efficacy conclusions remain exploratory and under clinical investigation. | Extensive long-term observational and guideline-backed evidence supports corticosteroid therapy as the current standard for improved strength and delayed disease progression in DMD. |
| Important limitations | Trial eligibility excludes patients with certain laboratory abnormalities, significant comorbidities, or recent use of other muscle-affecting drugs. Open-label design and lack of randomization limit comparative conclusions for effectiveness. Most participants had prior Givinostat exposure, which may affect generalizability. | Long-term corticosteroid use in DMD can cause side effects such as weakened bones, weight gain, growth effects, and other metabolic complications. Individual responses and side effects vary, and steroid management requires regular medical follow-up. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 1 year
Participants receive Givinostat oral suspension twice daily while in a fed state, with dose adjustments based on weight and safety monitoring.
Weekly visits for platelet count assessments during the first month, then every 2 weeks during the second month; further visit frequency as per study protocol
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Craig M McDonald, Michela Guglieri, Dragana Vučinić...
https://pubmed.ncbi.nlm.nih.gov/40830818/Italfarmaco
Lead Sponsor
Cromsource
Collaborating Sponsor